CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: TheSlowLane who wrote (176)	6/24/1997 3:55:00 PM
From: TheSlowLane	of 675

CNSI downgraded to from strong to speculative buy by Genesis Genesis Downgrades Cambridge Neuroscience to Speculative Buy June 24, 1997 12:50 PM SAN FRANCISCO, June 24 /PRNewswire/ -- Genesis Merchant Group Securities said it downgraded its rating on Cambridge Neuroscience, Inc. CNSI to speculative buy from strong buy after the company announced this morning it has temporarily suspended enrollment of its stroke study (Cerestat) following an interim analysis of the data. Genesis analyst Paul Boni said the enrollment suspension is a result of concerns raised from an interim analysis conducted on approximately 300 patients (out of a planned 900) with a 7-day follow-up (final data will be based on a 90-day follow-up). Boni noted that due to concerns regarding the risk/benefit ratio, all currently enrolled patients (600) will be followed for 90 days before any new patients are enrolled. Following the accumulation of this data, Boni expects the company to make a going-forward evaluation on the study. Boni anticipates that further analysis may provide a more positive outlook for the study. "First, it is possible that an imbalance in the patient groups caused the drug patients to look worse than the placebo patients. An analysis of a larger group, 600 patients vs. 300 patients, is more likely to balance the patient groups," he said, adding that longer follow-up may also favor efficacy of the risk/benefit ratio because benefits become more apparent over time. Even if subsequent data reveals continued negative findings, Boni said it is likely that the study will continue since the patients are generally younger and more tolerant of the side effects associated with Cerestat.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next